AKR1C3 and prostate cancer: To determine the magnitude of degradation of target proteins resulting from exposure to our small molecule inhibitor scaffold, we investigated the ability of inhibitor 3 and warhead 4 (Fig. 1) to degrade AKR1C3, AKR1C1/2, and ARv7 in 22Rv1 prostate cancer cells (Fig. 2).